Schizophrenia Clinical Trials in Miami Lakes, Florida
12 recruitingMiami Lakes, Florida
Showing 1–12 of 12 trials
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
Schizophrenia
Bristol-Myers Squibb116 enrolled8 locationsNCT07061288
Recruiting
Phase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences600 enrolled57 locationsNCT07114874
Recruiting
Phase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
SchizophreniaBipolar I Disorder
Alkermes, Inc.220 enrolled47 locationsNCT05303064
Recruiting
Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled73 locationsNCT06894212
Recruiting
Phase 3
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Schizophrenia
LB Pharmaceuticals Inc.456 enrolled13 locationsNCT07363577
Recruiting
Phase 2
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
Schizophrenia
MapLight Therapeutics500 enrolled5 locationsNCT07459647
Recruiting
Phase 3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company280 enrolled175 locationsNCT05304767
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
Schizophrenia
MapLight Therapeutics300 enrolled25 locationsNCT07038876
Recruiting
Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences284 enrolled21 locationsNCT06963034
Recruiting
Phase 2
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
Cognitive Impairment Associated With Schizophrenia (CIAS)
Kynexis B.V.150 enrolled13 locationsNCT07191483
Recruiting
Phase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
SchizophreniaAutism Spectrum DisorderBipolar Disorder
Intra-Cellular Therapies, Inc.500 enrolled50 locationsNCT06229210
Recruiting
Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Schizophrenia
Reviva Pharmaceuticals690 enrolled18 locationsNCT05184335